2 articles
Corporate consolidation in life sciences continues as GSK trims support roles and abandons a recent Hertfordshire commitment to meet global efficiency targets.
When the CEO of a $700 billion pharmaceutical giant publicly declares that the UK is "probably the worst country in Europe" for drug prices, it's a stark warning sign. Eli Lilly's Dave Ricks isn't just lamenting high taxes; he's signaling a broader institutional failure that's driving investment and innovation out of Britain. This analysis explores how bureaucratic short-termism and irrational pricing schemes are dismantling what was once a global leader in life sciences.